EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial

Richard Kazibwe iD, Matthew Singleton, Michael P Bancks, Juliana Namutebi, Aziz Hammoud, Michael Shapiro, Joseph Yeboah

Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 4011-4018

DOI: 10.1111/dom.15753 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.07.2024. Verfasst von Richard Kazibwe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Primary Prevention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health (NIH), CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the efficacy of aspirin use for primary prevention of cardiovascular disease (CVD) with incident atherosclerotic CVD and mortality in high‐risk type 2 diabetes. Method s In this post hoc analysis, we included participants in the ACCORD trial without CVD at baseline. The association between aspirin use and the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular [CV] death) and all‐cause mortality was evaluated using Cox proportional hazard analysis adjusting for demographics, CV risk factors and comorbidities.

Results

Eligible participants ( n = 6330) were aged 62.8 ± 5.9 years at baseline, 43.8% of the participants were female, and 3026 (47.8%) used aspirin. Over a median (interquartile range) follow‐up of 4.9 (4.1–5.7) years, the number (%) of primary outcome and all‐cause mortality events in those who used aspirin (vs. those who did not), was 196 (6.5) versus 229 (6.9) and 146 (4.8) versus 147 (4.5), respectively. The adjusted hazard ratios (95% confidence interval) associated with aspirin use for the primary outcome and all‐cause mortality were 0.94 (0.77–1.14) and 1.08 (0.85–1.36), respectively.

Conclusion

In high‐risk individuals with type 2 diabetes, the use of aspirin for primary prevention was not associated with a decreased risk of incident CVD or all‐cause mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinCardiovascular DiseasesDiabetes Mellitus, Type 2Primary PreventionAgedFemaleHumansMaleMiddle AgedDiabetic AngiopathiesMyocardial InfarctionPlatelet Aggregation InhibitorsProportional Hazards ModelsRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

aspirinprimary preventiontype 2 diabetes

Substanzen

AspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Cardiovascular Medicine, WellSpan Health, York, Pennsylvania, USA.
  • Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • School of Graduate Studies, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Centre for Prevention of Cardiovascular Disease, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID-Profile: Richard Kazibwe

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health (NIH)
  • CDC HHS
  • General Clinical Research Centers
  • National Heart, Lung, and Blood Institute
  • Centers for Disease Control and Prevention

Zitieren

APA

Kazibwe, R., Singleton, M., Bancks, M. P., Namutebi, J., Hammoud, A., Shapiro, M., & Yeboah, J. (2024). Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial. Diabetes, Obesity and Metabolism, 26(9), 4011-4018. https://doi.org/10.1111/dom.15753

Vancouver

Kazibwe R, Singleton M, Bancks MP, Namutebi J, Hammoud A, Shapiro M, et al. Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial. Diabetes, Obesity and Metabolism. 2024;26(9):4011-4018. doi:10.1111/dom.15753

BibTeX
@article{Kazibwe2024,
  author = {Kazibwe, Richard and Singleton, Matthew and Bancks, Michael P and Namutebi, Juliana and Hammoud, Aziz and Shapiro, Michael and Yeboah, Joseph},
  title = {Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {4011--4018},
  doi = {10.1111/dom.15753}
}
Kostenlos starten →